HER2-positive

2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Carisma Therapeutics
Carisma TherapeuticsPA - Philadelphia
2 programs
2
CT-0508Phase 11 trial
CT-0525Phase 11 trial
Active Trials
NCT04660929Active Not RecruitingEst. Dec 2024
NCT06254807Active Not RecruitingEst. Mar 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Carisma TherapeuticsCT-0525
Carisma TherapeuticsCT-0508

Clinical Trials (2)

NCT06254807Carisma TherapeuticsCT-0525

CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors

Start: Jan 2024Est. completion: Mar 2026
Phase 1Active Not Recruiting
NCT04660929Carisma TherapeuticsCT-0508

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Start: Feb 2021Est. completion: Dec 2024
Phase 1Active Not Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space